Media.Player

Combined Blockade of VEGFR-3 and VLA-1 to Improve Transplant Survival

Technology Benefits

90% graft survival local or systemic administration demonstrated in mouse model

Technology Application

corneal transplants in low-risk and high-risk settings corneal vascularization in various diseases other tissue or organ transplant other immune- or lymphatic-related disorders e.g. cancer metastasis

Detailed Technology Description

None

Supplementary Information

Patent Number: US20150102907A1
Application Number: US14050742A
Inventor: Hadizad, Peyman
Priority Date: 10 Oct 2013
Priority Number: US20150102907A1
Application Date: 10 Oct 2013
Publication Date: 16 Apr 2015
IPC Current: G07C000900 | G08C001702
US Class: 34000564
Assignee Applicant: Motorola Mobility LLC,Libertyville | Motorola Mobility LLC,Libertyville
Title: Method and System for Controlling Access to a Restricted Location
Usefulness: Method and System for Controlling Access to a Restricted Location
Summary: Method for controlling physical access to a restricted location through wireless medium e.g. Near Field Communication (NFC) medium, a personal area network (PAN) medium, and a local area network (LAN) medium, and visual image such as an alphanumeric code, a visual representation of an object, a visual representation of a person, a pattern, a bar code, and a quick response (QR) code (all claimed).
Novelty: Method for controlling physical access to restricted location through wireless medium e.g. near field communication and visual representation of object, involves determining whether to grant access to restricted location

Industry

Robot/Machinery

Application No.

9364535

Others

Related Materials

Combined Blockade of VEGFR-3 and VLA-1 Markedly Promotes High-Risk Corneal Transplant Survival

Additional Technologies by these Inventors

• Live Imaging of Corneal Lymphatic Vessels
• Modulation of Ang-2 to Treat Pathologic Lymphangiogenesis
• Methods and Materials to Treat Lymphangiogenesis
• Modulation Of Lymphatic Valve And Vessel Formation To Treat Diseases, Such As Trasplant Rejection

Tech ID/UC Case

22498/2012-097-0

Related Cases

2012-097-0

*Abstract

Among all solid organ or tissue transplantations, corneal transplantation is the most successful, with a 2-year survival rate of 90% in patients with inflamed and avascular (low-risk) graft beds. Unfortunately, the rejection rate reaches as high as 50-90% when the grafting is performed on inflamed and highly vascularized (high-risk) corneas. Many patients who are blind as a result of corneal diseases fall in this category after traumatic, inflammatory, infectious, or chemical damage. Such patients are not considered as good candidates for transplantation surgery and have to give up their hope for vision restoration. To address these challenges, investigators at University of California Berkeley have developed a technical strategy using a combined blockade of vascular endothelial growth factor receptor-3 (VEGFR-3) and very late antigen-1 (VLA-1) that markedly improves high-risk corneal transplant transparency and survival. This strategy suppresses lymphatic vessels in grafted corneas. It provides a new and powerful strategy to combat high-risk corneal transplant rejection. The strategy may also be used to treat low-risk transplant rejection and other immune- or lymphatic-related diseases. It can be locally or systemically administered.

*IP Issue Date

Jun 14, 2016

*Principal Investigator

Name: Lu Chen

Department:

Name: Hui Zhang

Department:

Country/Region

USA